Improved preoperative risk stratification in endometrial carcinoma patients: external validation of the ENDORISK Bayesian network model in a large population-based case series.
Bayesian network
Endometrial carcinoma
Lymph nodes
Personalized medicine
Risk stratification
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
24
05
2022
accepted:
18
07
2022
medline:
5
7
2023
pubmed:
9
8
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
Preoperative risk stratification of newly diagnosed endometrial carcinoma (EC) patients has been hindered by only moderate prediction performance for many years. Recently ENDORISK, a Bayesian network model, showed high predictive performance. It was the aim of this study to validate ENDORISK by applying the model to a population-based case series of EC patients. ENDORISK was applied to a retrospective cohort of women surgically treated for EC from 2003 to 2013. Prediction accuracy for LNM as well as 5-year DSS was investigated. The model's overall performance was quantified by the Brier score, discriminative performance by area under the curve (AUC). A complete dataset was evaluable from 247 patients. 78.1% cases were endometrioid histotype. The majority of patients (n = 156;63.2%) had stage IA disease. Overall, positive lymph nodes were found in 20 (8.1%) patients. Using ENDORISK predicted probabilities, most (n = 156;63.2%) patients have been assigned to low or very low risk group with a false-negative rate of 0.6%. AUC for LNM prediction was 0.851 [95% confidence interval (CI) 0.761-0.941] with a Brier score of 0.06. For 5-year DSS the AUC was 0.698 (95% CI 0.595-0.800) as Brier score has been calculated 0.09. We were able to successfully validate ENDORISK for prediction of LNM and 5-year DSS. Next steps will now have to focus on ENDORISK performance in daily clinical practice. In addition, incorporating TCGA-derived molecular subtypes will be of key importance for future extended use. This study may support further promoting of data-based decision-making tools for personalized treatment of EC.
Identifiants
pubmed: 35939115
doi: 10.1007/s00432-022-04218-4
pii: 10.1007/s00432-022-04218-4
pmc: PMC10314833
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3361-3369Informations de copyright
© 2022. The Author(s).
Références
Cancer. 2017 Mar 1;123(5):802-813
pubmed: 28061006
Lancet. 2016 Mar 12;387(10023):1094-1108
pubmed: 26354523
Updates Surg. 2016 Jun;68(2):149-54
pubmed: 26826083
J Clin Pathol. 2010 May;63(5):410-5
pubmed: 20418232
PLoS Med. 2020 May 15;17(5):e1003111
pubmed: 32413043
J Clin Oncol. 2020 Oct 10;38(29):3388-3397
pubmed: 32749941
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Cochrane Database Syst Rev. 2017 Oct 02;10:CD007585
pubmed: 28968482
Am J Obstet Gynecol. 2017 May;216(5):459-476.e10
pubmed: 27871836
Histopathology. 2020 Jan;76(1):52-63
pubmed: 31846532
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Lancet. 2009 Jan 10;373(9658):125-36
pubmed: 19070889
Artif Intell Med. 2004 Mar;30(3):201-14
pubmed: 15081072
CA Cancer J Clin. 2019 Jul;69(4):258-279
pubmed: 31074865
Am J Surg Pathol. 2013 Jun;37(6):874-81
pubmed: 23629444
Ann Oncol. 2018 May 1;29(5):1180-1188
pubmed: 29432521
J Pathol. 2021 Apr;253(4):355-365
pubmed: 33368243
Recent Results Cancer Res. 2016;208:107-136
pubmed: 27909905
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Am Soc Clin Oncol Educ Book. 2017;37:435-442
pubmed: 28561715
Mod Pathol. 2013 Dec;26(12):1594-604
pubmed: 23807777
J Cancer Res Clin Oncol. 2019 Jan;145(1):213-221
pubmed: 30460411